|
subsections menu :
Contacts
|
Content :
Press releases 2004
December 23, 2004 Approval of the merger of Aventis with and into Sanofi-aventis
December 22, 2004 Sanofi-aventis to reorganise short-term financing
December 20, 2004 Sanofi-aventis receives Patent Office’s Notice of Allowance on its reissuance application for Lovenox ‘618 patent.
December 10, 2004 Taxotere® (docetaxel) regimen significantly improves survival in women with node positive early stage breast cancer
December 9, 2004 Update of patent litigation schedules in the United States for Plavix® and Lovenox®
December 7, 2004 First International Registry of Patients with Early Stage Breast Cancer Launched
November 29, 2004 Eloxatin™ (oxaliplatin for injection) based therapy combined with bevacizumab (Avastin™) significantly improves survival in patients with advanced colorectal cancer
November 25, 2004 Proposed Relocation of Aventis’ headquarters from Strasbourg to Paris
November 9, 2004 Aventis, part of the sanofi-aventis Group, announced termination of its agreements with Genta
November 5, 2004 Eloxatin™ (oxaliplatin for injection) receives FDA approval for the treatment of colon cancer following surgery (adjuvant treatment)
November 4, 2004 Possibility of increase in price of mandatory offer of sanofi-aventis to shareholders of Hoechst AG to EUR 56.50 per Hoechst shareCash compensation for the squeeze-out set by Aventis amounts to Eur 56.60 per Hoechst share.
November 4, 2004 European Union Approval for Taxotere® (docetaxel) in Prostate Cancer
October 26, 2004 Aventis Receives Approvable Letter from U.S. Food and Drug Administration for Alvesco® (ciclesonide) for Treatment of Persistent Asthma
October 21, 2004 Sales momentum maintained, rapid progress on integration - Sustained growth in proforma combined net sales: 10.5% for the first nine months of 2004
October 14, 2004 Proposed Merger of Aventis into sanofi-aventis
October 8, 2004 Strengthening of the Alliance on Actonel® between the Sanofi-aventis Group and Procter & Gamble
October 1, 2004 sanofi-aventis launches its mandatory offer to the shareholders of Hoechst Aktiengesellschaft. Offer document cleared by German Financial Supervisory Authority (BaFin)
September 22, 2004 New appointments in the sanofi-aventis Group
September 22, 2004 Appointments at the Communications Department of the sanofi-aventis Group
September 17, 2004 Eloxatin® to receive expanded indication in Europe for early stage colorectal cancer treatment
September 16, 2004 The sanofi-aventis Group thanks its team members and shareholders and launches its new visual identity
September 16, 2004 Final results of sanofi-aventis’ offer for Aventis: After subsequent offering period, sanofi-aventis holds 98.03% of Aventis share capital
September 7, 2004 sanofi-aventis’ offer for Aventis subsequent offering period has expired
September 6, 2004 Appointments of a hundred managers in 70 countries in the sanofi-aventis group
September 1, 2004 Agnès Garcia-Gibot is appointed Director of International Internal Communications and Corporate Image for Sanofi-Aventis
August 31, 2004 Excellent first half of 2004 for Sanofi-Synthelabo. Strong growth in EPS* in the first half of 2004: 21.6% on a reported basis; 32.8% at 2003 exchange rates
August 30, 2004 Olivier Jacquesson becomes head of Business Development
August 23, 2004 Mandatory Publication pursuant to Sections 35 sub-sec. 1, 10 sub-sec. 3 Securities Acquisition and Takeover Act (WpÜG) – Mandatory Offer
August 20, 2004 Birth of Sanofi-Aventis, the world's 3rd largest pharmaceutical company, ranking number 1 in Europe
August 12, 2004 Broad success of Sanofi-Synthélabo’s offer for Aventis
August 9, 2004 Sanofi-Synthélabo’s offer for Aventis. Provisional results of the offers
July 31, 2004 Sanofi-Synthélabo’s offer for Aventis. Tender period has expired
July 29, 2004 FTC Clears Sanofi-Synthélabo’s offer for Aventis shares
July 21, 2004 Very strong sales growth in the first half of 2004: consolidated sales: 4,460 million euros, up 18.9% on a comparable basis, up 14.3% on a reported basis, developed sales: up 25.5% on a comparable basis
July 20, 2004 Teva Pharmaceuticals’ ANDA does not challenge the product patent for Avapro® (irbesartan)
July 15, 2004 The U.S. Federal Trade Commission’s Bureau of Competition and Economics has completed its review of Sanofi-Synthélabo's proposed acquisition of Aventis
June 25, 2004 Sanofi-Synthelabo and Pfizer conclude an agreement on the divestment of Campto® (irinotecan) conditional upon completion of Sanofi-Synthelabo's offer for Aventis
June 24, 2004 Annual general meeting
June 23, 2004 Sanofi-Synthelabo’s offer for Aventis : expiration date of offers
June 22, 2004 Closing date of Sanofi-Synthelabo's offer on Aventis postponed to July 30, 2004
June 21, 2004 Draft structure of Sanofi-Aventis Management Committee
June 14, 2004 Sanofi-Synthelabo's offer for Aventis : Adjustment of offer terms on approval of Aventis dividend
June 4, 2004 New indications for Arixtra® in the United States: the treatment of acute deep venous thrombosis and acute pulmonary embolism
June 3, 2004 ELOXATIN™ study in New England Journal Of Medicine demonstrates significant benefit over standard therapy in early stage colon cancerEloxatin™ Based Adjuvant Chemotherapy Provides 23 Percent Reduction in Risk of Colon Cancer Recurrence
June 1, 2004 Sanofi-Synthelabo's offer for Aventis. Expiration date of offers
May 26, 2004 Sanofi-Synthelabo's offer for Aventis : U.S. offer extended to Wednesday, June 30, 2004
May 26, 2004 General Meeting of Sanofi-Synthelabo Shareholders: Sanofi-Synthelabo’s Offer for Aventis
May 14, 2004 Sanofi-Synthelabo’s Shareholders Meeting and offer for Aventis
May 5, 2004 Sanofi-Synthélabo’s Offer for Aventis: request for Additional Information from the Federal Trade Commission
May 4, 2004 Postponement of Sanofi-Synthélabo General Meeting of May 24, 2004
April 27, 2004 Approval by the European Commission of the planned acquisition of Aventis by Sanofi-Synthelabo
April 26, 2004 Agreement between Sanofi-Synthelabo and Aventis to create Sanofi-Aventis
April 22, 2004 1st quarter 2004 sales :Sustained and very strong sales growth
April 15, 2004 Press release dated April 15, 2004
April 13, 2004 Sanofi-Synthelabo to sell to GlaxoSmithKline Arixtra®, Fraxiparine® and Notre Dame de Bondeville plant
April 13, 2004 Sanofi-Synthélabo Commences U.S. Offer for Aventis
April 5, 2004 Sanofi-Synthélabo's Offer for Aventis
March 25, 2004 Alfuzosin 10 mg OD (Xatral® OD) shows beneficial effect in patients with acute urinary retentionNeed for BPH-related surgery reduced
March 19, 2004 Financing of the offer on AVENTISSanofi-Synthelabo announces today the successful completion of the first round of syndication of the 12 billion euro credit facility* put in place in connection with its offer for Aventis.
March 12, 2004 Publication of financial statements 2003
March 9, 2004 Two pivotal studies indicate ACOMPLIA™ (rimonabant) offers a novel approach to cardiovascular risk management in overweight/obese people and smokersRIO-LIPIDS AND STRATUS-US Study Results Announced Today at American College of Cardiology Annual Meeting
February 16, 2004 Outstanding 2003 performance : sales growth, 15.6% on a comparable basis, 2003 EPS growth, 21.5%, very positive R&D results
February 4, 2004 Sanofi-Synthelabo to acquire all of Taisho's 49% interest in the joint venture company Sanofi-Synthelabo-Taisho Pharmaceutical Co.Sanofi-Synthelabo announced today that it has reached an agreement with Taisho Pharmaceutical Co. Ltd. ("Taisho"), whereby Sanofi-Synthelabo will acquire all of Taisho's 49% interest in the joint venture company Sanofi-Synthelabo-Taisho Pharmaceutical Co., Ltd.
January 26, 2004 Sanofi-Synthelabo announces offer for Aventis's shares
January 22, 2004 Continued strong consolidated sales growth in 2003: 15.6 % on a comparable basis 8.1% on a reported basisVery robust growth in developed sales in 2003: 20.4 % on a comparable basis
January 19, 2004 ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancerAdjuvant Regimen with ELOXATIN™ shows a major Reduction in Disease Recurrence
January 16, 2004 Press release dated January 16, 2004
January 12, 2004 Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancerELOXATIN™ now indicated for “the treatment of advanced carcinoma of the colon or rectum in combination with infusional 5FU/LV."
January 7, 2004 Sanofi-Synthelabo to acquire all interests in Arixtra®, idraparinux and other oligosaccharides from OrganonSanofi-Synthelabo announces today that it has reached agreement with NV Organon to acquire all of Organon interests relating to Arixtra® (fondaparinux sodium), idraparinux and other oligosaccharides such as the hexadecasaccharide.
January 7, 2004 ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in EuropeAfter a successful Mutual Recognition Procedure, ELOXATIN® will be granted the full indication : "Treatment of Metastatic Colorectal Cancer"
|
Slots : |
Press releases and press packs are intended to journalists, investors and shareholders.
